So Many Loved Ones Can Still Be Saved
COMING SOON: RiViveTM over-the-counter naloxone nasal spray (3.0 mg)
RiVive is an affordable, over-the-counter, naloxone nasal spray from Harm Reduction Therapeutics that is currently under FDA review. If approved by the FDA in the summer of 2023, Harm Reduction Therapeutics anticipates making RiVive available by early 2024.
About Harm Reduction Therapeutics
Harm Reduction Therapeutics, Inc. (HRT) is a 501(c)(3) nonprofit pharmaceutical company whose mission is to increase access to a free or low-cost, easy-to-use naloxone nasal spray that will save lives that would otherwise be lost to opioid overdose.
For years, harm reduction groups and public health experts have called the need for over-the-counter naloxone to be clear, unambiguous, and represent an urgent unmet medical and public health need. HRT developed RiVive, a 3.0 mg naloxone nasal spray, to help address both (1) the high cost of prescription naloxone products, and (2) lack of over-the-counter access.